Gastrointestinal tract absorption enhancement

Gastrointestinal tract absorption enhancement" does **not** refer to a specific molecule, receptor, enzyme, transporter, or other canonical therapeutic target. Instead, it describes a broad physiological process or pharmaceutical strategy aimed at increasing the uptake of drugs or nutrients from the gastrointestinal tract into systemic circulation. Various mechanisms and interventions have been studied to enhance GI absorption: - **Paracellular pathway modulation:** Agents like citrate can increase intestinal absorption by opening tight junctions between epithelial cells in the proximal bowel[1]. - **Transcellular transport facilitation:** Coformulation with excipients such as SNAC (N-[8-(2-hydroxybenzoyl) aminocaprylate]) can transiently enhance transcellular stomach absorption for certain peptides without affecting tight junctions[3]. - **Carrier-mediated pathways:** Some compounds utilize carrier proteins (e.g., P-glycoprotein substrates), and their intestinal uptake may be enhanced by inhibiting efflux transporters with agents like verapamil[2]. - **Nanodroplet formation:** Drug-rich nanodroplets formed via liquid–liquid phase separation can improve oral drug bioavailability by facilitating direct uptake into enterocytes in the small intestine[6]. Because "gastrointestinal tract absorption enhancement" is not itself a discrete molecular entity but rather an umbrella term for various strategies and mechanisms that increase GI drug/nutrient uptake, it should not be classified as a canonical therapeutic target.

Not applicable; this is not a specific molecular target but rather a physiological process or strategy.